Insider · CIK 0001529371
Cheryl Cohen
Files at CLDX (Celldex Therapeutics, Inc.), IBRX (ImmunityBio, Inc.). First filing Oct 6, 2026, latest Oct 6, 2026.
Cheryl Cohen files SEC Form 4 as director at IBRX (ImmunityBio, Inc.), and also at CLDX (Celldex Therapeutics, Inc.). Since Oct 6, 2026, Cheryl Cohen has reported 0 open-market buys worth $0 and 1 open-market sell worth $851k, the latest filed on Oct 6, 2026.
A track record needs three past buys with six months of prices behind them; Cheryl Cohen has 0, so none is measured yet.
The newest scored trade: sold $851k of IBRX on Oct 2, 2026, filed Oct 6, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $851k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IBRX: ImmunityBio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | ImmunityBio, Inc. | $851k 81,056 shares | -45% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock10b5-1 | +55,979 | $2.98 | $167k | 181,365 | 7 d ago |
| Oct 2, 2026 | IBRX ImmunityBio, Inc. | SOpen-market sale Common Stock10b5-1 | -81,056 | $10.50 | $851k | 100,309 | 7 d ago |
| Oct 2, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -55,979 | $0.00 | $0 | 55,979 | 7 d ago |
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +26,000 | $0.00 | $0 | 26,000 | Jun 29, 2026 |
| Jun 9, 2026 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +65,600 | $0.00 | $0 | 65,600 | Jun 10, 2026 |
| Jun 18, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +162,786 | $0.00 | $0 | 162,786 | Jun 20, 2025 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
Questions about Cheryl Cohen
Answered from the filings on this page, as of the latest one.
Is Cheryl Cohen buying or selling?
In the last 12 months Cheryl Cohen reported 0 open-market buys worth $0 and 1 open-market sell worth $851k on SEC Form 4; the latest was sold $851k of IBRX on Oct 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Cheryl Cohen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Cheryl Cohen has 0.
Where does Cheryl Cohen file Form 4?
Cheryl Cohen has filed Form 4 at IBRX (ImmunityBio, Inc.); CLDX (Celldex Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.